Sutro Biopharma Inc [STRO] stock is trading at $0.72, up 32.36%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The STRO shares have gain 10.28% over the last week, with a monthly amount drifted -52.17%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sutro Biopharma Inc [NASDAQ: STRO] stock has seen the most recent analyst activity on March 17, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Wedbush downgraded its rating to Neutral on March 14, 2025, and dropped its price target to $2. On March 14, 2025, downgrade downgraded it’s rating to Mkt Perform. BofA Securities downgraded its rating to a Underperform and decreased its price target to $1 on March 14, 2025. BofA Securities initiated its recommendation with a Buy and recommended $12 as its price target on May 08, 2024. Deutsche Bank started tracking with a Buy rating for this stock on November 09, 2023, and assigned it a price target of $12. In a note dated October 06, 2023, Oppenheimer initiated an Outperform rating and provided a target price of $10 on this stock.
Sutro Biopharma Inc [STRO] stock has fluctuated between $0.54 and $5.28 over the past year. Currently, Wall Street analysts expect the stock to reach $8.67 within the next 12 months. Sutro Biopharma Inc [NASDAQ: STRO] shares were valued at $0.72 at the most recent close of the market. An investor can expect a potential return of 1104.17% based on the average STRO price forecast.
Analyzing the STRO fundamentals
Sutro Biopharma Inc [NASDAQ:STRO] reported sales of 62.04M for the trailing twelve months, which represents a drop of -86.98%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -3.84%, Pretax Profit Margin comes in at -3.63%, and Net Profit Margin reading is -3.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -2.24 and Total Capital is -0.93. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5867 points at the first support level, and at 0.4533 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8167, and for the 2nd resistance point, it is at 0.9133.
Ratios To Look Out For
For context, Sutro Biopharma Inc’s Current Ratio is 2.60. Further, the Quick Ratio stands at 2.60, while the Cash Ratio is 1.44. Considering the valuation of this stock, the price to sales ratio is 0.97, the price to book ratio is 1.33.
